Skip to main content
. 2016 Jul 13;16:462. doi: 10.1186/s12885-016-2536-2

Fig. 6.

Fig. 6

B16F10 and LLC tumours that had previously received cell-based Reovirus vaccine as therapy for established tumour were excised and analysed for cytokine production. Both groups were evaluated – those that had received the vaccine s.c. and IV. a B16F10 tumours showed no particular pattern of cytokine production post exposure relative to route of vaccine administration. b LLC tumours showed a down-regulation of cytokine levels in almost all evaluated. Statistical significance is indicated by the stars above each bar (*P < 0.05, **P < 0.01, ***P < 0.0001)